Literature DB >> 3112862

Regression of mediastinal Hodgkin disease after therapy: evaluation of time interval.

L B North, L M Fuller, J A Sullivan-Halley, F B Hagemeister.   

Abstract

Ninety-one patients with Hodgkin disease of the upper torso who had mediastinal masses were studied to determine the frequency of residual mass and the time required for resolution or stabilization of the mass. In 72 of these patients, radiographs from sufficient intervals were available for determination of the rate of regression. In 62 patients (86%), the mediastinum returned to normal width within 11 months, regardless of the size of the mass. The mediastinum returned to normal in all but one patient with small masses. The intrathoracic relapse rate did not correlate with the regression time of the masses, but relapse occurred more than twice as often in patients with residual mediastinal widening.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3112862     DOI: 10.1148/radiology.164.3.3112862

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

Review 1.  Assessment of response to therapy using conventional imaging.

Authors:  Sheila C Rankin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-27       Impact factor: 9.236

2.  Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study.

Authors:  M Bendini; C Zuiani; M Bazzocchi; G Dalpiaz; F Zaja; E Englaro
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

3.  Magnetic resonance imaging for the assessment of residual masses after treatment of non-Hodgkin's lymphomas.

Authors:  C Montalbán; J L Rodríguez-García; L Mazairas; I Ayala; J Marcos-Robles
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

4.  Childhood T-cell lymphoblastic lymphoma--does early resolution of mediastinal mass predict for final outcome? The United Kingdom Children's Cancer Study Group (UKCCSG).

Authors:  S F Shepherd; R P A'Hern; C R Pinkerton
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

5.  Lymphoma: a clinical view.

Authors:  M Hill; N Maisey
Journal:  Cancer Imaging       Date:  2000-10-11       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.